To define the molecular basis for rituximab resistance we developed several RRCL and demonstrated changes in CD20 expression/structure and membrane reorganization following rituximab therapy.

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

The CD20 protein presents a unique arrangement, featuring four membrane-spanning domains. Notably, both the amino and carboxy termini of the protein are positioned within the cytoplasm. An intriguing ...